Pamela R. Matias-Garcia,Cavin K. Ward-Caviness,Laura M. Raffield,Xu Gao,Yan Zhang,Rory Wilson,Xin Gao,Jana Nano,Andrew Bostom,Elena Colicino,Adolfo Correa,Brent Coull,Charles Eaton,Lifang Hou,Allan C. Just,Sonja Kunze,Leslie Lange,Ethan Lange,Xihong Lin,Simin Liu,Jamaji C. Nwanaji-Enwerem,Alex Reiner,Jincheng Shen,Ben Schottker,Pantel Vokonas,Yinan Zheng,Bessie Young,Joel Schwartz,Steve Horvath,Ake Lu,Eric A. Whitsel,Wolfgang Koenig,Jerzy Adamski,Juliane Winkelmann,Hermann Brenner,Andrea A. Baccarelli,Christian Gieger,Annette Peters,Nora Franceschini,Melanie Waldenberger

Abstract:Background The difference between an individual's chronological and DNA methylation predicted age (DNAmAge), termed DNAmAge acceleration (DNAmAA), can capture life-long environmental exposures and age-related physiological changes reflected in methylation status. Several studies have linked DNAmAA to morbidity and mortality, yet its relationship with kidney function has not been assessed. We evaluated the associations between seven DNAm aging and lifespan predictors (as well as GrimAge components) and five kidney traits (estimated glomerular filtration rate [eGFR], urine albumin-to-creatinine ratio [uACR], serum urate, microalbuminuria and chronic kidney disease [CKD]) in up to 9688 European, African American and Hispanic/Latino individuals from seven population-based studies. Results We identified 23 significant associations in our large trans-ethnic meta-analysis (p < 1.43E-03 and consistent direction of effect across studies). Age acceleration measured by the Extrinsic and PhenoAge estimators, as well as Zhang's 10-CpG epigenetic mortality risk score (MRS), were associated with all parameters of poor kidney health (lower eGFR, prevalent CKD, higher uACR, microalbuminuria and higher serum urate). Six of these associations were independently observed in European and African American populations. MRS in particular was consistently associated with eGFR (beta = - 0.12, 95% CI = [- 0.16, - 0.08] change in log-transformed eGFR per unit increase in MRS, p = 4.39E-08), prevalent CKD (odds ratio (OR) = 1.78 [1.47, 2.16], p = 2.71E-09) and higher serum urate levels (beta = 0.12 [0.07, 0.16], p = 2.08E-06). The "first-generation" clocks (Hannum, Horvath) and GrimAge showed different patterns of association with the kidney traits. Three of the DNAm-estimated components of GrimAge, namely adrenomedullin, plasminogen-activation inhibition 1 and pack years, were positively associated with higher uACR, serum urate and microalbuminuria. Conclusion DNAmAge acceleration and DNAm mortality predictors estimated in whole blood were associated with multiple kidney traits, including eGFR and CKD, in this multi-ethnic study. Epigenetic biomarkers which reflect the systemic effects of age-related mechanisms such as immunosenescence, inflammaging and oxidative stress may have important mechanistic or prognostic roles in kidney disease. Our study highlights new findings linking kidney disease to biological aging, and opportunities warranting future investigation into DNA methylation biomarkers for prognostic or risk stratification in kidney disease.

DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes

DNA methylation trajectories and accelerated epigenetic aging in incident type 2 diabetes

DNA methylation age of blood predicts all-cause mortality in later life

DNA methylation age acceleration is associated with risk of diabetes complications

Associations between epigenetic aging and diabetes mellitus in a Swedish longitudinal study

Blood DNA Methylation Sites Predict Death Risk in a Longitudinal Study of 12, 300 Individuals

Integrative analysis of clinical and epigenetic biomarkers of mortality

Heterogeneity of increased biological age in type 2 diabetes correlates with differential tissue DNA methylation, biological variables, and pharmacological treatments

Development and validation of DNA methylation scores in two European cohorts augment 10-year risk prediction of type 2 diabetes

Genome-wide association studies identify 137 loci for DNA methylation biomarkers of ageing

DNA methylation GrimAge strongly predicts lifespan and healthspan

DNA Methylation-Based Biomarkers of Age Acceleration and All-Cause Death, Myocardial Infarction, Stroke, and Cancer in Two Cohorts: the NAS, and KORA F4

DNA methylation‐based biomarkers of aging were slowed down in a two‐year diet and physical activity intervention trial: the DAMA study

Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging

DNA Methylation Clocks and Their Predictive Capacity for Aging Phenotypes and Healthspan

DNA methylation and 28-year cardiovascular disease risk in type 1 diabetes: the Epidemiology of Diabetes Complications (EDC) cohort study

Biological Ageing and the Risks of All-Cause and Cause-Specific Mortality among People with Diabetes: a Prospective Cohort Study.

DNAm-based Signatures of Accelerated Aging and Mortality in Blood Are Associated with Low Renal Function.

Mortality Associations With DNA Methylation-Based Biological Aging and Physical Functioning Measures Across a 20-Year Follow-up Period

Utility of DNA Methylation as a Biomarker in Aging and Alzheimer's Disease

Blood DNA Methylation and Type 2 Diabetes Mellitus